
cbdMD YCBD
$ 0.92
-1.1%
Quarterly report 2025-Q4
added 02-17-2026
cbdMD Operating Cash Flow 2011-2026 | YCBD
Annual Operating Cash Flow cbdMD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -353 K | -4.3 M | -15 M | -14.1 M | -10.7 M | -15.4 M | -5.57 M | -2.33 M | -2.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -353 K | -15.4 M | -7.84 M |
Quarterly Operating Cash Flow cbdMD
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -812 K | - | - | - | -318 K | - | - | - | -106 K | - | - | - | -2.06 M | -13 M | - | - | -5.47 M | -9.76 M | -5.15 M | - | -2.19 M | -10.3 M | -9.15 M | -2.19 M | -4.87 M | -9.06 M | -4.46 M | -4.87 M | -1.16 M | -4.84 M | -3.55 M | -1.16 M | -1.82 M | -1.42 M | -1.28 M | -1.82 M | -529 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -106 K | -13 M | -4.06 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
-166 M | $ 1.19 | 1.71 % | $ 128 M | ||
|
China Pharma Holdings
CPHI
|
-466 K | $ 0.61 | - | $ 10.7 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 4.07 | 3.83 % | $ 57.2 M | ||
|
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | ||
|
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | ||
|
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
3.84 M | $ 52.5 | -0.54 % | $ 1.71 B | ||
|
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
-206 M | $ 11.16 | 1.82 % | $ 571 M | ||
|
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M | ||
|
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
-18 M | $ 4.37 | 1.63 % | $ 271 M | ||
|
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.44 | 1.41 % | $ 402 M | ||
|
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | ||
|
Pacira BioSciences
PCRX
|
189 M | $ 23.61 | 0.85 % | $ 1.09 B | ||
|
Bausch Health Companies
BHC
|
1.03 B | $ 6.16 | 2.33 % | $ 2.25 B | ||
|
Sundial Growers
SNDL
|
-155 M | $ 1.55 | -0.32 % | $ 3.37 M | ||
|
Tilray
TLRY
|
7.91 M | $ 7.97 | 0.6 % | $ 4.93 B | ||
|
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
14.2 M | $ 4.07 | 0.99 % | $ 536 M | ||
|
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
363 M | $ 14.41 | -1.37 % | $ 1.98 B | ||
|
Aurora Cannabis
ACB
|
-211 M | $ 3.85 | 1.58 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
-9.41 M | $ 0.91 | -3.58 % | $ 21.2 M | ||
|
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.38 | 2.82 % | $ 132 M | ||
|
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
49.6 M | $ 11.84 | -0.84 % | $ 841 M | ||
|
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.9 | 2.11 % | $ 3.6 M | ||
|
Solid Biosciences
SLDB
|
-100 M | $ 6.36 | 2.92 % | $ 260 M | ||
|
SCYNEXIS
SCYX
|
60.2 M | $ 0.77 | -1.72 % | $ 36.8 M | ||
|
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
-21.7 M | $ 2.65 | 1.56 % | $ 357 M | ||
|
TherapeuticsMD
TXMD
|
-159 M | $ 2.22 | -1.33 % | $ 23.2 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | ||
|
Viatris
VTRS
|
3 B | $ 16.2 | 0.84 % | $ 19.6 B |